Biotech Firm PepGen Receives 'Moderate Buy' Rating from Analysts

Analysts see potential in the company's precision gene editing therapies for rare genetic diseases.

Apr. 13, 2026 at 8:34am

Got story updates? Submit your updates here. ›

An extreme close-up of complex, highly engineered biotech machinery and equipment, conveying the advanced science behind PepGen's precision gene editing therapies.PepGen's cutting-edge gene editing technology holds promise for rare disease patients, though the company's early-stage pipeline still carries significant risk.San Diego Today

Shares of PepGen, Inc. (NASDAQ:PEPG) have received an average recommendation of 'Moderate Buy' from the six analysts currently covering the stock. One analyst has rated the stock as a 'sell', while five have given it a 'buy' rating. The average 12-month target price among analysts is $11.80.

Why it matters

PepGen is a clinical-stage biotech company developing precision gene editing therapies for rare genetic diseases. The 'Moderate Buy' rating from analysts suggests they see potential in the company's platform and pipeline, which could provide hope for patients with these debilitating conditions.

The details

Several equity research analysts have weighed in on PepGen's stock. Wedbush decreased their target price from $9 to $5, but maintained an 'outperform' rating. Weiss Ratings gave the stock a 'sell (d-)' rating. Oppenheimer initiated coverage with an 'outperform' rating and a $15 price target. Guggenheim also lifted their price target from $6 to $7, while keeping a 'buy' rating.

  • PepGen's stock opened at $1.64 on Monday, April 13, 2026.
  • The company's one-year low was $1.01, and its one-year high was $7.80.

The players

PepGen, Inc.

A clinical-stage biotechnology company headquartered in San Diego, California, developing precision gene editing therapies to address rare genetic diseases.

Wedbush

An investment research firm that decreased its target price for PepGen's stock but maintained an 'outperform' rating.

Weiss Ratings

A financial research firm that gave PepGen's stock a 'sell (d-)' rating.

Oppenheimer

An investment bank that initiated coverage of PepGen with an 'outperform' rating and a $15 price target.

Guggenheim

An investment firm that lifted its price target for PepGen's stock from $6 to $7, while keeping a 'buy' rating.

Got photos? Submit your photos here. ›

What they’re saying

“Wedbush decreased their target price on shares of PepGen from $9.00 to $5.00 and set an 'outperform' rating on the stock.”

— Wedbush, Investment Research Firm

“Weiss Ratings restated a 'sell (d-)' rating on shares of PepGen.”

— Weiss Ratings, Financial Research Firm

“Oppenheimer started coverage on PepGen and set an 'outperform' rating and a $15.00 price target for the company.”

— Oppenheimer, Investment Bank

“Guggenheim lifted their price target on PepGen from $6.00 to $7.00 and gave the stock a 'buy' rating.”

— Guggenheim, Investment Firm

What’s next

Investors will be closely watching PepGen's progress as the company continues to advance its precision gene editing therapies through clinical trials. The stock's performance will likely be influenced by updates on the development of its lead programs for rare genetic diseases.

The takeaway

The 'Moderate Buy' rating from analysts suggests they see promise in PepGen's platform, which could provide new treatment options for patients with debilitating rare genetic disorders. However, the stock's volatility and the company's early-stage pipeline indicate there is still significant risk and uncertainty surrounding its long-term prospects.